🚀 Big News Alert! 🚀 We are thrilled to announce that we have our first randomized patient in our groundbreaking pragmatic clinical trial! 🌟

🇩🇪 First patient enrolled in Germany in the #CARE1 trial! A major milestone made possible thanks to the dedication of German investigators, research teams and coordinating staff. @UniklinikEssen #ClinicalResearch #ClinicalTrials #CancerResearch #Germany #CARE1PCT

🇧🇪 Milestone reached for #CARE1: the first patient has been enrolled in Belgium! A huge thank you to the Belgian sites, investigators and teams, and to @SaintLucUCLouvain for their continued support. Looking forward to the next inclusions! #ClinicalTrials

🇩🇪 Another milestone for #CARE1! The first German sites are now open and ready to join the CARE1 pragmatic clinical trial. Welcome to: @UniklinikEssen @UniklinikDUS @uniklinik_hd #ClinicalTrials #Oncology #CancerResearch

🇧🇪 Belgium continues to strengthen the CARE1 network! We are delighted to announce the activation of 7 Belgian sites in the CARE1 pragmatic clinical trial. @ClinUnivStLuc #CARE1PCT #CARE1Project #ClinicalTrials #Oncology

🎥 Prof. Laurence Albiges and Dr. Elena Verzoni share key highlights from the #CARE1Project, including an update on the progress of the #CARE1 trial in Italy. Thank you to the entire team at @IstTumori ! youtu.be/coGlAtGPHAk?si=kd9S… via @YouTube

🇳🇱 Welcome to LUMC! We are pleased to announce the activation of @LUMC_Leiden as a participating site in the CARE1 pragmatic clinical trial. LUMC becomes the 6th active CARE1 site in the Netherlands. #CARE1PCT #CARE1Project #ClinicalTrials #Oncology

🇨🇿 The CARE1 network continues to expand! We are pleased to announce the activation of a new site in the Czech Republic: @FNPlzen #CARE1 #ClinicalTrials #CancerResearch #CARE1PCT

🇩🇪 Germany is now open for #CARE1! Another important milestone for the CARE1 pragmatic clinical trial as our European network continues to grow. Thank you to all partners and to the National Coordinating Center: @UniklinikEssen #CARE1PCT #Oncology #ClinicalTrials

🇧🇪 Belgium is now open for #CARE1! We're excited to welcome new Belgian sites to the CARE1 pragmatic clinical trial, expanding our European research network and bringing innovative cancer care research closer to patients. #CancerResearch #Oncology #ClinicalTrials #CARE1PCT #CARE1

CARE1 expands in the UK 🇬🇧 New site open: 📍 @RoyalFreeNHS Strengthening our phase III trial across Europe to improve treatment strategies in 1L mRCC. #clinicaltrials #care1project #RCC #care1pct @IKCCorg @ACTION4KC

CARE1 expands in the Netherlands 🇳🇱 New sites open: 📍 Maastricht UMC+ @MaastrichtUMC 📍 Leiden University Medical Center @GlobalLumc Strengthening our phase III trial footprint across Europe to improve treatment strategies in 1L mRCC. #clinicaltrials #oncology #RCC

Dr Nguyen from City of Hope highlighting during #ASCO26 pRCC educational session the *role of PD-L1 IHC *staining as a candidate *biomarker* to enrich for response to IO… This is the running hypothesis being prospectively tested in CARE-1 PCT in ccRCC in first line setting.

CARE1 PI's at #ASCO2026 🔬 In 1L mRCC, IO-IO vs IO-TKI remains an open question — no biomarker to guide choice. 👉 CARE1 (EU-funded phase III) is the only head-to-head RCT tackling this. 🎯 Right treatment, right patient. #clinicaltrials #oncology #care1pct #care1project

On #ClinicalTrialsDay, we highlight the impact of clinical research in oncology. CARE1 contributes to advancing pragmatic trials and generating evidence to support better patient outcomes. #CancerResearch #ClinicalTrials #Oncology #CARE1 #BeatCancer #CTD2026

Proud to see CARE1 cited in “Navigating the Maze: Clinical Trials and Second‑Line Therapy Decisions" at #IKCSEU26! Thank you to Bernard Escudier, member of our Patient Advisory Board, for sharing his valuable insight. #CARE1Project @OncoAlert @KidneyCancer @AssoARTuR

At #IKCSEU26, Olivier Exertier emphasized the key role of patient representatives such as @IKCCorg and @AssoARTuR in shaping EU‑funded programmes like CARE1. #PatientEngagement #CARE1 #EUProjects @KidneyCancer @ACTION4KC @OncoAlert

At #IKCSEU26 Paris, during session during session on Molecular Biomarkers and Patient Stratification Yann Vano explained how the CARE1 trial may clarify the role of PD‑L1 as a biomarker for routine treatment decisions during the biomarker session. @OncoAlert @KidneyCancer

Prof. Laurence Albiges presenting the CARE1 Pragmatic Clinical Trial at the @AACR Special Conference on RAS Oncogenesis & Therapeutics. #AACR #CARE1 #RCC #ClinicalTrials #CancerResearch @TurajlicLab @AlbigesL

🎉 New CARE1 site in the Czech Republic! A warm welcome to @FnMotol Fakultní nemocnice v Motole – University Hospital Motol, now the 4th CARE1 site in the country. Thank you to all teams driving this study forward! #CARE1Trial #ClinicalResearch #Oncology #CzechRepublic

📣 CARE1 expands in the Netherlands! Welcoming @MMC Máxima Medisch Centrum and Isala as new participating sites — bringing more access to innovative cancer research across the country. #CARE1Trial #ClinicalResearch #Oncology #Netherlands @NKI_nl